Reclassification and the introduction of biologicals

Nature Reviews Nephrology

Volumn 9, Issue 2, 2013, Pages 70-72

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HLA DQ ANTIGEN; METHOTREXATE; MYELOBLASTIN; MYELOPEROXIDASE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; DISEASE CLASSIFICATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION; MICROSCOPIC POLYANGIITIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY; VASCULITIS; WEGENER GRANULOMATOSIS; BIOLOGICAL THERAPY; CLASSIFICATION; IMMUNOLOGY; REVIEW; SYSTEMIC VASCULITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL THERAPY; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; MICROSCOPIC POLYANGIITIS; SYSTEMIC VASCULITIS;

MLCS; MLOWN;

EID: 84873170522     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.284     Document Type: Short Survey

References (10)

1. Jennette, J. C. et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. http://dx.doi.org/10. 1002/art.37715.
2. Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214-223 (2012).
3. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003).
4. de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann. Intern. Med. 150, 670-680 (2009).
5. Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955-960 (2012).
6. Faurschou, M. et al. Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472-3477 (2012).
7. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
8. Cartin-Ceba, R. et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 64, 3770-3778 (2012).
9. Terrier, B. et al. Management of noninfectious mixed cryoglobulinemic vasculitis: data from 242 cases included in the CryoVas survey. Blood 119, 5996-6004 (2012).
10. De Vita, S. et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64, 843-853 (2012).